Drug Device Combination
Products

The National Medical Products Administration (NMPA) defines drug-device combination products as medical products composed of both drugs and medical devices, integrated into a single entity.

To register a combination product with the NMPA, you must first determine the product’s Primary Mode of Action (PMOA):

Drug-led combination products registration applications must be submitted to the Center for Drug Evaluation (CDE)
Device-led combination products must be submitted to the Center for Medical Device Evaluation (CMDE).

If the device PMOA is unclear, applicants can apply for an attribute definition from the NMPA’s Center for Medical Device Standards Management (CMDSM) before submitting the premarket approval application.

Single entity combination products
Drug products inside delivery device

Joint Evaluation of Drug Device 
Combination Products

During a joint evaluation, the CDE and CMDE collaborate to assess the product's safety, effectiveness, and quality control. Each center issues an evaluation report covering its respective component, and the leading unit consolidates these findings into an overall evaluation report. This report is then submitted to the relevant NMPA department for administrative approval.

For drug-led combination products, the CDE leads the evaluation. If a joint evaluation is required, the application dossier is transferred to the CMDE for synchronized evaluation.

For device-led combination products, the CMDE leads the evaluation. If a joint evaluation is required, the dossier is transferred to the CDE.

During a joint evaluation, the CDE and CMDE collaborate to assess the product's safety, effectiveness, and quality control. Each center issues an evaluation report covering its respective component, and the leading unit consolidates these findings into an overall evaluation report. This report is then submitted to the relevant NMPA department for administrative approval.

Our China Drug-Device Combination Product Services

With expertise in both pharmaceutical and medical device regulations, we assist with the classification, registration and compliance of both drug and device-led combination products.

Our services include:

Regulatory Pathway Assessment

If uncertain, we assist in applying for an attribute definition with the Center for Medical Device Standards Management (CMDSM).
Determine the product’s primary mode of action (PMOA) to classify it as drug-led or device-led.

Registration Strategy Development

Develop a customized regulatory strategy aligned with the requirements of the Center for Drug Evaluation (CDE) or the Center for Medical Device Evaluation (CMDE), depending on the product’s classification.
Coordinate with both centers for joint evaluations as required.

Dossier Preparation & Submission

Ensure that documentation covers both drug and device components, including safety, efficacy, and quality control data including the necessary type testing in China.
Prepare and compile the registration dossier, ensuring compliance with NMPA guidelines.
Submit the application through the NMPA online platform.

Clinical Trial Application (CTA)

Ensure compliance with Good Clinical Practice (GCP) standards for both drug and device components.
Assist in obtaining approval for clinical trials if required.

Communication & Coordination with Regulatory Authorities

Liaise with the CDE and CMDE to facilitate the evaluation process.
Address enquiries and provide additional documentation as requested by regulators.

Post-Approval Compliance

Ensure compliance with post-market surveillance requirements, including pharmacovigilance and medical device vigilance.
Support registration renewals, variations, and amendments.

Request a Proposal from Our Life Sciences Team about Your Combination Product

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

How China IVD Risk Classification Determines Your NMPA Registration Pathway

Learn how China IVD risk classification works under NMPA rules and see common compliance pitfalls to avoid.

July 13, 2026
How China IVD Risk Classification Determines Your NMPA Registration Pathway

A Guide to South Korea Medical Device Regulation for Global Manufacturers

Understand South Korea’s medical device regulations, from classification to approval and post-market compliance.

July 10, 2026
A Guide to South Korea Medical Device Regulation for Global Manufacturers

Understanding South Korea's Strategic Roadmap for Digital Medical Product Safety Management

Learn how MFDS’s Digital Medical Product Safety Management Roadmap will shape future compliance requirements for digital medical products in Korea.

July 10, 2026
Understanding South Korea's Strategic Roadmap for Digital Medical Product Safety Management
Stock photo of a Korean man in his early 30s sitting comfortably in a bright, contemporary apartment in South Korea, casually reviewing a health monitoring app on his smartphone while wearing a small continuous glucose monitor (CGM) sensor on his arm.

What Is the MFDS? Understanding South Korea’s Medical Device Authority

Learn how South Korea’s Ministry of Food and Drug Safety regulates medical devices, including classification, application review and post-market duties.

July 10, 2026
What Is the MFDS? Understanding South Korea’s Medical Device Authority

Explained: South Korea Medical Device Classification (Class I, II, III, & IV)

Learn how South Korea medical device classification works under the MFDS.

July 10, 2026
Explained: South Korea Medical Device Classification (Class I, II, III, & IV)
Stock photo of an adult South Korean patient wearing a continuous glucose monitor (CGM) on the upper arm during a routine appointment in a modern hospital outpatient clinic

China NMPA Fee Catalogue for Drugs & Medical Devices

Learn the latest China NMPA registration fees for imported and domestic drugs and medical devices.

July 10, 2026
China NMPA Fee Catalogue for Drugs & Medical Devices
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

Pharmaceutical Development & Strategy Consulting

We assess your product’s market viability and identify development gaps to enhance readiness. We create tailored regulatory and clinical strategies aligned with Chinese health authority requirements, ensuring clear and compliant communication for streamlined approval.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Latest Insights

View More

China Expands MRI Registration Requirements Under New 2026 Review Guideline

Manufacturers seeking MRI registration in China must meet expanded technical, software, and validation requirements.

July 16, 2026
China Expands MRI Registration Requirements Under New 2026 Review Guideline
Chinese male MRI technician in a clinical, sterile medical imaging room. The man has a warm, focused expression and is wearing a dark blue medical-style t-shirt

China Releases First Regulatory Guidance for Brain-Computer Interface Medical Devices

China's new BCI medical device guidance establishes classification and naming principles, giving manufacturers a clearer pathway to NMPA registration.

July 14, 2026
China Releases First Regulatory Guidance for Brain-Computer Interface Medical Devices

Singapore HSA Implements CMC Declaration Requirement Following eCTD Adoption

HSA now requires CMC validity declarations and accepts eCTD submissions, strengthening therapeutic product registration requirements.

July 2, 2026
Singapore HSA Implements CMC Declaration Requirement Following eCTD Adoption
medium shot of a Singaporean male worker inside a clean, modern manufacturing facility.

TFDA Simplifies Drug Clinical Trial Application Requirements Effective July 2026

Taiwan's TFDA will reduce clinical trial submission documents and ease decentralized trial requirements for sponsors from July 1, 2026.

June 30, 2026
TFDA Simplifies Drug Clinical Trial Application Requirements Effective July 2026
Stock photograph inside a bright, modern hospital clinical research consultation room in Taiwan. A Taiwanese clinical research physician in a white lab coat sits across from a Taiwanese adult trial participant.

China Revises Drug Clinical Trial GCP to Align with ICH E6(R3)

New rules strengthen data governance and raise sponsor oversight duties from September 2026.

June 29, 2026
China Revises Drug Clinical Trial GCP to Align with ICH E6(R3)
quality control laboratory inside a modern pharmaceutical manufacturing facility in China.

Taiwan Proposes New Online Drug Enforcement Obligations Under Pharmaceutical Affairs Act

New rules expand platform accountability and regulatory oversight, reshaping how pharmaceutical products are promoted, sold, and controlled online.

June 29, 2026
Taiwan Proposes New Online Drug Enforcement Obligations Under Pharmaceutical Affairs Act
Previous
Previous

Get in Touch with Our Life Sciences Team

And discover how we can support you in achieving approval for your drug-device combination product in China.

Request Proposal